Cargando…

Identification of a Small Molecular Insulin Receptor Agonist With Potent Antidiabetes Activity

Insulin replacement therapy is a widely adopted treatment for all patients with type 1 diabetes and some with type 2 diabetes. However, injection of insulin has suffered from problems such as tissue irritation, abscesses, discomfort, and inconvenience. The use of orally bioactive insulin mimetics th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiang, Guifen, Xue, Shenghui, Yang, Jenny J., Du, Guanhua, Pang, Xiaobin, Li, Xiaoting, Goswami, Devrishi, Griffin, Patrick R., Ortlund, Eric A., Chan, Chi Bun, Ye, Keqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2014
Materias:	Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964510/ https://www.ncbi.nlm.nih.gov/pubmed/24651808 http://dx.doi.org/10.2337/db13-0334

Ejemplares similares

Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain
por: Scarlett, Jarrad M., et al.
Publicado: (2019)

Selective Small-Molecule Agonists of G Protein–Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice
por: Tan, Carina P., et al.
Publicado: (2008)

FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents
por: Mu, James, et al.
Publicado: (2012)

Antidiabetic Effects of Pterosin A, a Small-Molecular-Weight Natural Product, on Diabetic Mouse Models
por: Hsu, Feng-Lin, et al.
Publicado: (2013)

Sustained Antidiabetic Effects of a Berberine-Containing Chinese Herbal Medicine Through Regulation of Hepatic Gene Expression
por: Zhao, Hai-Lu, et al.
Publicado: (2012)

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

Anti-Insulin Receptor Antibodies Improve Hyperglycemia in a Mouse Model of Human Insulin Receptoropathy
por: Brierley, Gemma V., et al.
Publicado: (2020)

Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle
por: Dineen, Stacey L., et al.
Publicado: (2015)

Recommendations for the Definition of Clinical Responder in Insulin Preservation Studies
por: Beam, Craig A., et al.
Publicado: (2014)

SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans
por: Nishizaki, Harunobu, et al.
Publicado: (2021)

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans
por: Koska, Juraj, et al.
Publicado: (2015)

Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin
por: Holden, Sarah E, et al.
Publicado: (2011)

Effect of Rosiglitazone on Bone Quality in a Rat Model of Insulin Resistance and Osteoporosis
por: Sardone, Laura D., et al.
Publicado: (2011)

Methazolamide Is a New Hepatic Insulin Sensitizer That Lowers Blood Glucose In Vivo
por: Konstantopoulos, Nicky, et al.
Publicado: (2012)

Obesity independently predicts responders to biphasic insulin 50/50 (Humalog Mix50 and Insuman Comb 50) following conversion from other insulin regimens: a retrospective cohort study
por: Mamza, J, et al.
Publicado: (2014)

Changes in Glucose and Fat Metabolism in Response to the Administration of a Hepato-Preferential Insulin Analog
por: Edgerton, Dale S., et al.
Publicado: (2014)

A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic Control
por: Bhaskar, Vinay, et al.
Publicado: (2012)

Adenylyl Cyclase Type 5 Deficiency Protects Against Diet-Induced Obesity and Insulin Resistance
por: Ho, David, et al.
Publicado: (2015)

Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials
por: Sosenko, Jay M., et al.
Publicado: (2020)

Fibroblast Growth Factor 21 Action in the Brain Increases Energy Expenditure and Insulin Sensitivity in Obese Rats
por: Sarruf, David A., et al.
Publicado: (2010)

Engineered Commensal Bacteria Reprogram Intestinal Cells Into Glucose-Responsive Insulin-Secreting Cells for the Treatment of Diabetes
por: Duan, Franklin F., et al.
Publicado: (2015)

Pck1 Gene Silencing in the Liver Improves Glycemia Control, Insulin Sensitivity, and Dyslipidemia in db/db Mice
por: Gómez-Valadés, Alicia G., et al.
Publicado: (2008)

Postprandial Platelet Activation Is Related to Postprandial Plasma Insulin Rather Than Glucose in Patients With Type 2 Diabetes
por: Spectre, Galia, et al.
Publicado: (2012)

Proinsulin-Transferrin Fusion Protein as a Novel Long-Acting Insulin Analog for the Inhibition of Hepatic Glucose Production
por: Wang, Yan, et al.
Publicado: (2014)

GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers
por: Christensen, Alexander S., et al.
Publicado: (2020)

Insulin Reduces Cerebral Ischemia/Reperfusion Injury in the Hippocampus of Diabetic Rats: A Role for Glycogen Synthase Kinase-3β
por: Collino, Massimo, et al.
Publicado: (2009)

Phenotypic Type 2 Diabetes in Obese Youth: Insulin Sensitivity and Secretion in Islet Cell Antibody–Negative Versus –Positive Patients
por: Tfayli, Hala, et al.
Publicado: (2009)

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice
por: Xu, Jing, et al.
Publicado: (2009)

Infusion of Mesenchymal Stem Cells Ameliorates Hyperglycemia in Type 2 Diabetic Rats: Identification of a Novel Role in Improving Insulin Sensitivity
por: Si, Yiling, et al.
Publicado: (2012)

Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes
por: Chow, Elaine, et al.
Publicado: (2023)

Activation of Peroxisome Proliferator–Activated Receptor-β/-δ (PPAR-β/-δ) Ameliorates Insulin Signaling and Reduces SOCS3 Levels by Inhibiting STAT3 in Interleukin-6–Stimulated Adipocytes
por: Serrano-Marco, Lucía, et al.
Publicado: (2011)

Relationship between primary school healthy eating and physical activity promoting environments and children’s dietary intake, physical activity and weight status: a longitudinal study in the West Midlands, UK
por: Garden, Elizabeth Mairenn, et al.
Publicado: (2020)

Anti-tumor Activity of Toll-Like Receptor 7 Agonists
por: Chi, Huju, et al.
Publicado: (2017)

HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs
por: Fritsche, Andreas, et al.
Publicado: (2019)

The Natural PPAR Agonist Linoleic Acid Stimulated Insulin Release in the Rat Pancreas
por: LAI, Min-Chuan, et al.
Publicado: (2013)

Antidiabetic and Antilipidemic Effect of Musa balbisiana Root Extract: A Potent Agent for Glucose Homeostasis in Streptozotocin-Induced Diabetic Rat
por: Kalita, Himadri, et al.
Publicado: (2016)

Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects
por: Zhang, Hongkai, et al.
Publicado: (2015)

High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis
por: Yan, Yu-Ling, et al.
Publicado: (2015)

CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist
por: Kevin, Richard C., et al.
Publicado: (2019)

Novel TRPV1 Channel Agonists With Faster and More Potent Analgesic Properties Than Capsaicin
por: Duarte, Yorley, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_63131q4546813g9jbi5cgsd07q